Hepion Pharmaceuticals (HEPA) gives VP 1.35M options at $0.08

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) reported that director and officer Chase LoPriore, VP, Corp. Dev., received a grant of stock options for 1,345,500 shares of Common Stock on August 19, 2026. The options have a conversion or exercise price of $0.08 per share and expire on August 19, 2036. According to the vesting terms, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over six months from the grant date. Following this grant, LoPriore holds 1,345,500 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LoPriore Chase

Role VP, Corp. Dev.

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	1,345,500	$0.00	$0.00

Holdings After Transaction: Stock Options — 1,345,500 shares (Direct)

Footnotes (1)

1. F1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.

Key Figures

Stock options granted: 1,345,500 options Exercise price: $0.08 per share Options vesting upon grant: 336,375 options +3 more

6 metrics

Stock options granted 1,345,500 options Grant of Stock Options on August 19, 2026

Exercise price $0.08 per share Conversion or exercise price of granted stock options

Options vesting upon grant 336,375 options Portion of options that vest immediately on grant

Remaining vesting period 6 months Unvested options vest monthly over six months from grant date

Expiration date August 19, 2036 Expiration of the granted stock options

Underlying common shares 1,345,500 shares Underlying Common Stock covered by the granted options

Key Terms

Stock Options, conversion or exercise price, vest upon grant, underlying security

4 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

conversion or exercise price financial

"conversion_or_exercise_price: "0.0800""

vest upon grant financial

"336,375 options vest upon grant and the remaining amount vests"

underlying security financial

"underlying_security_title: "Common Stock""

FAQ

What insider transaction did HEPA report for Chase LoPriore on this Form 4?

HEPA reported that Chase LoPriore received a grant of 1,345,500 stock options on August 19, 2026, representing an acquisition of derivative securities tied to the company’s Common Stock.

What is the exercise price of the stock options granted to Chase LoPriore at HEPA?

The stock options granted to Chase LoPriore have a conversion or exercise price of $0.08 per share for the underlying Hepion Pharmaceuticals, Inc. Common Stock.

How do the new HEPA stock options granted to Chase LoPriore vest?

According to the filing, 336,375 options vest upon grant, and the remaining options vest in equal amounts monthly over 6 months from the date of grant.

When do Chase LoPriore’s newly granted HEPA stock options expire?

The newly granted stock options to Chase LoPriore expire on August 19, 2036, giving a 10-year term from the grant date of August 19, 2026.

How many HEPA stock options does Chase LoPriore hold after this grant?

Following this reported grant, Chase LoPriore holds 1,345,500 stock options directly, as shown in the post-transaction holdings field of the Form 4.

Were the HEPA option transactions by Chase LoPriore under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not checked (aff_10b5_one is false), indicating the reported option grant was not affirmed as being made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 04:34 PM Accepted by SEC EDGAR 08/21/2026 - 04:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LoPriore Chase

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Corp. Dev.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.08	08/19/2026		A		1,345,500		08/19/2026(1)	08/19/2036	Common Stock	1,345,500	$0	1,345,500	D

Explanation of Responses:

1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.

	/s/ Chase LoPriore	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)